{"id":"chop-plus-lanzoprazole","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CHOP is a standard chemotherapy regimen used primarily in lymphoma treatment, while lansoprazole reduces gastric acid production by inhibiting the H+/K+-ATPase pump. The combination may be used to manage H. pylori-associated gastric lymphoma or to provide gastroprotection during chemotherapy. Lansoprazole helps prevent chemotherapy-induced gastrointestinal toxicity and treats underlying acid-related disease.","oneSentence":"CHOP Plus Lansoprazole combines chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) with a proton pump inhibitor to treat Helicobacter pylori infection and gastric conditions.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:05:48.080Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastric mucosa-associated lymphoid tissue (MALT) lymphoma associated with Helicobacter pylori"},{"name":"Lymphoma with gastric involvement requiring gastroprotection"}]},"trialDetails":[{"nctId":"NCT03647072","phase":"PHASE3","title":"PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy","status":"RECRUITING","sponsor":"Sherief Abd-Elsalam","startDate":"2018-08-01","conditions":"Lymphoma","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CHOP Plus Lanzoprazole 60"],"phase":"phase_3","status":"active","brandName":"CHOP Plus Lanzoprazole","genericName":"CHOP Plus Lanzoprazole","companyName":"Sherief Abd-Elsalam","companyId":"sherief-abd-elsalam","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CHOP Plus Lansoprazole combines chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) with a proton pump inhibitor to treat Helicobacter pylori infection and gastric conditions. Used for Gastric mucosa-associated lymphoid tissue (MALT) lymphoma associated with Helicobacter pylori, Lymphoma with gastric involvement requiring gastroprotection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}